Asia
It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 7, 2020.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
AstraZeneca signed a deal with Beijing-based Shenzhen Kangtai Biological Products to manufacture AstraZeneca and the University of Oxford’s COVID-19 vaccine in mainland China.
GentiBio focuses on engineered regulatory T-cells (EngTregs) to treat autoimmune, alloimmune, autoinflammatory and allergic diseases.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.
Merck entered into an exclusive licensing deal with Hanmi Pharmaceutical for the development, manufacture and commercialization of efinopegdutide for nonalcoholic steatohepatitis (NASH).
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.
Regeneron Pharmaceuticals and BioNTech have inked a strategic collaboration to combine BioNTech’s BNT111 FixVac product candidate and Regeneron and Sanofi’s checkpoint inhibitor Libtayo (cemiplimab) for the treatment of melanoma.
As usual, there was plenty of clinical trial news last week. Here’s a look.
PRESS RELEASES